Home Responses Observed in Three-Quarters of Heavily Pre-Treated Multiple Myeloma Patients Receiving KEYTRUDA (pembrolizumab) Combined With Lenalidomide and Dexamethasone
 

Keywords :   


Responses Observed in Three-Quarters of Heavily Pre-Treated Multiple Myeloma Patients Receiving KEYTRUDA (pembrolizumab) Combined With Lenalidomide and Dexamethasone

2015-12-07 13:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Findings Presented at the 57th American Society of Hematology Annual Meeting Demonstrate Activity of KEYTRUDA Therapy in Previously-Treated Multiple Myeloma Patients When Combined with Lenalidomide and Dexamethasone KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today new study findings investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in combination with lenalidomide and low-dose dexamethasone (two commonly used treatments for multiple myeloma) in patients whose disease has progressed after at least two lines of prior therapy, including a proteasome inhibitor and an IMiD (immune modulatory drug). Language: English Contact: Media:Pamela Eisele, 267-305-3558orKim Hamilton, 908-391-0131orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: multiple combined observed receiving

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
27.11adabat
27.11slp
27.11Nana
27.11
27.11
27.11Daiwa LABRAX ags87lml
27.11 Disney100 & Disney 100
27.11
More »